HRP20240164T1 - Pripravci i postupci za liječenje aktivne tuberkulozne infekcije mikobakterijama - Google Patents
Pripravci i postupci za liječenje aktivne tuberkulozne infekcije mikobakterijama Download PDFInfo
- Publication number
- HRP20240164T1 HRP20240164T1 HRP20240164TT HRP20240164T HRP20240164T1 HR P20240164 T1 HRP20240164 T1 HR P20240164T1 HR P20240164T T HRP20240164T T HR P20240164TT HR P20240164 T HRP20240164 T HR P20240164T HR P20240164 T1 HRP20240164 T1 HR P20240164T1
- Authority
- HR
- Croatia
- Prior art keywords
- vaccine
- tuberculosis infection
- use according
- seq
- alkyl
- Prior art date
Links
- 201000008827 tuberculosis Diseases 0.000 title claims 17
- 238000000034 method Methods 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 claims 16
- 208000015181 infectious disease Diseases 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 8
- 208000036981 active tuberculosis Diseases 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 4
- 229940021747 therapeutic vaccine Drugs 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- OPGTXAUDXWCGFI-UHFFFAOYSA-N [1-[[6-[[3-(3-dodecanoyloxytetradecanoylamino)-6-(hydroxymethyl)-5-phosphonooxy-4-(3-tetradecanoyloxytetradecanoyloxy)oxan-2-yl]oxymethyl]-2,4,5-trihydroxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] hexadecanoate Chemical group OC1C(O)C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(O)OC1COC1C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)C(OC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(OP(O)(O)=O)C(CO)O1 OPGTXAUDXWCGFI-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims 1
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 108010065839 Capreomycin Proteins 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 1
- 208000000616 Hemoptysis Diseases 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 229930189077 Rifamycin Natural products 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- 229960004909 aminosalicylic acid Drugs 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000007503 antigenic stimulation Effects 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229960004602 capreomycin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 229960003077 cycloserine Drugs 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 229960000285 ethambutol Drugs 0.000 claims 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims 1
- 229960002001 ethionamide Drugs 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 229940124307 fluoroquinolone Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229960003350 isoniazid Drugs 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 206010029410 night sweats Diseases 0.000 claims 1
- 230000036565 night sweats Effects 0.000 claims 1
- 229960001699 ofloxacin Drugs 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 229960005206 pyrazinamide Drugs 0.000 claims 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 1
- 230000007420 reactivation Effects 0.000 claims 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 claims 1
- 229940081192 rifamycins Drugs 0.000 claims 1
- 230000007480 spreading Effects 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 229960005322 streptomycin Drugs 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (14)
1. Cjepivo koje sadrži farmaceutski pripravak koji sadrži fuzijski polipeptid, pri čemu fuzijski polipeptid:
(a) sadrži kombinaciju antigena Rv1813, Rv3620 i Rv2608 iz vrsta mikobakterija, pri čemu antigen Rv1813 sadrži slijed aminokiselina SEQ ID NO: 5, antigen Rv3620 sadrži slijed aminokiselina SEQ ID NO: 6, a antigen Rv2608 sadrži slijed aminokiselina SEQ ID NO: 7 i antigeni su kovalentno povezani, ili
(b) sadrži kombinaciju antigena Rv1813, Rv3620, Rv2608 i Rv3619 iz vrsta mikobakterija, pri čemu antigen Rv1813 sadrži slijed aminokiselina SEQ ID NO: 5, antigen Rv3620 sadrži slijed aminokiselina SEQ ID NO: 6, antigen Rv2608 sadrži slijed aminokiselina SEQ ID NO: 7, a antigen Rv3619 sadrži slijed aminokiselina SEQ ID NO: 8 i antigeni su kovalentno povezani, ili,
(c) izabran je iz polipeptida koji sadrži slijed aminokiselina naveden u SEQ ID NO: 1, polipeptida koji sadrži slijed aminokiselina naveden u SEQ ID NO: 2, ili polipeptida koji sadrži slijed aminokiselina naveden u SEQ ID NO: 3 ili SEQ ID NO: 4,
pri čemu cjepivo sadrži adjuvant, za upotrebu u postupku liječenja aktivne tuberkulozne infekcije u sisavaca, pri čemu je aktivna tuberkulozna infekcija naznačena time da se mikobakterije tuberkuloze umnožavaju, razmnožavaju, šire ili aktivno množe eksponencijalnom, logaritamskom ili polulogaritamskom brzinom u organu sisavca i pri čemu je navedeno liječenje u kombinaciji s jednim ili više kemoterapijskih agensa učinkovito protiv infekcije bakterijom M. tuberculosis.
2. Cjepivo za upotrebu prema zahtjevu 1, pri čemu cjepivo potiče imunosni odgovor na tuberkulozu i pri čemu liječenje umanjuje vrijeme potrebno za djelovanje kemoterapije protiv aktivne tuberkulozne infekcije.
3. Cjepivo za upotrebu prema zahtjevu 2, pri čemu je vrijeme potrebno za djelovanje kemoterapije umanjeno na najviše 3 mjeseca, 5 mjeseci ili 7 mjeseci.
4. Cjepivo za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu se aktivna tuberkulozna infekcija dovodi u vezu s kliničkim simptomom slabosti, umora, groznice, zimice, gubitka tjelesne težine, gubitka apetita, anoreksije ili noćnog znojenja ili bilo kojom kombinacijom tih simptoma.
5. Cjepivo za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu je aktivna tuberkulozna infekcija aktivna primarna infekcija bakterijom M. tuberculosis, reaktivacijska tuberkulozna infekcija, plućna aktivna tuberkulozna infekcija ili višestruko rezistentna (MDR) infekcija bakterijom M. tuberculosis.
6. Cjepivo za upotrebu prema zahtjevu 5, pri čemu se plućna aktivna tuberkulozna infekcija dovodi u vezu s kliničkim simptomom ustrajnog kašlja, guste sluzi, boli u prsima ili hemoptize ili bilo kojom kombinacijom tih simptoma.
7. Cjepivo za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu je aktivna tuberkulozna infekcija utvrđena testom odabranim iz skupine koja se sastoji od testa bojenja acidorezistentnih bacila (AFS), testa bakterijskih kultura, testa otpuštanja interferona gama (IGR), kožnog testa i bojenja unutarstaničnih citokina u punoj krvi ili izoliranih mononuklearnih stanica iz periferne krvi nakon antigenske stimulacije.
8. Cjepivo za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu je sisavac prethodno imuniziran bacilom Calmette-Guérin (BCG).
9. Cjepivo za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu je jedan ili više kemoterapijskih agensa amikacin, aminosalicilna kiselina, kapreomicin, cikloserin, etambutol, etionamid, izoniazid, kanamicin, pirazinamid, rifamicini, streptomicin, ofloksacin, ciprofloksacin, klaritromicin, azitromicin ili fluorokinoloni ili kombinacija tih agensa.
10. Cjepivo za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu:
sisavac prvo prima jedan ili više kemoterapijskih agensa tijekom duljeg vremenskog razdoblja, a potom primi terapijsko cjepivo,
sisavac prvo primi terapijsko cjepivo, a potom prima jedan ili više kemoterapijskih agensa tijekom duljeg vremenskog razdoblja ili
primjena jednog ili više kemoterapijskih agensa i terapijskog cjepiva je istodobna.
11. Cjepivo za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu je adjuvant glukopiranozil lipid A (GLA), koji ima sljedeću strukturu:
[image]
pri čemu su R1, R3, R5 i R6 alkil C11-C20, a R2 i R4 alkil C9-C20.
12. Cjepivo za upotrebu prema zahtjevu 11, pri čemu su:
R1, R3, R5 i R6 alkil C11-C14, a R2 i R4 alkil C12-15, R1, R3, R5 i R6 su alkil C11, a R2 i R4 alkil C13 ili su R1, R3, R5 i R6 alkil C11, a R2 i R4 alkil C9.
13. Cjepivo za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu je sisavac čovjek.
14. Cjepivo za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu sisavac prima terapijsko cjepivo jednom ili više puta zaredom nakon početne primjene, pri čemu tuberkulozna infekcija koja ostane u sisavcu nakon jedne primjene ili više primjena zaredom može biti, ali ne mora, aktivna tuberkulozna infekcija.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679612P | 2012-08-03 | 2012-08-03 | |
| US201361791213P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/053482 WO2014042780A1 (en) | 2012-08-03 | 2013-08-02 | Compositions and methods for treating an active mycobacterium tuberculosis infection |
| EP13836324.7A EP2879701B1 (en) | 2012-08-03 | 2013-08-02 | Compositions and methods for treating an active mycobacterium tuberculosis infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240164T1 true HRP20240164T1 (hr) | 2024-04-12 |
Family
ID=50278593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240164TT HRP20240164T1 (hr) | 2012-08-03 | 2013-08-02 | Pripravci i postupci za liječenje aktivne tuberkulozne infekcije mikobakterijama |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20150182612A1 (hr) |
| EP (2) | EP2879701B1 (hr) |
| JP (1) | JP2015525784A (hr) |
| CN (1) | CN104812404A (hr) |
| BR (1) | BR112015002483A2 (hr) |
| ES (1) | ES2969734T3 (hr) |
| HR (1) | HRP20240164T1 (hr) |
| MX (1) | MX2015001557A (hr) |
| PT (1) | PT2879701T (hr) |
| RU (1) | RU2659149C2 (hr) |
| WO (1) | WO2014042780A1 (hr) |
| ZA (2) | ZA201501242B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018014270A (es) * | 2016-05-21 | 2019-02-14 | Infectious Disease Res Inst | Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa. |
| GB201909953D0 (en) * | 2019-07-11 | 2019-08-28 | Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency | Diagnostic reagents |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| GB2605538A (en) | 2020-03-23 | 2022-10-05 | Hdt Bio Corp | Compositions and methods for delivery of RNA |
| MX2023007648A (es) | 2020-12-23 | 2023-08-29 | Access To Advanced Health Inst | Adyuvantes de vacuna de solanesol y métodos para prepararlos. |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| ES2105262T3 (es) | 1992-05-18 | 1997-10-16 | Minnesota Mining & Mfg | Dispositivo de suministro de farmaco a traves de las mucosas. |
| PT761231E (pt) | 1992-06-25 | 2000-06-30 | Smithkline Beecham Biolog | Composicao de vacina contendo adjuvantes |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6194388B1 (en) | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| BR9909915A (pt) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
| AU773204C (en) | 1998-08-10 | 2005-05-19 | Antigenics Llc | Compositions of CPG and saponin adjuvants and methods thereof |
| US7472098B2 (en) | 2000-02-14 | 2008-12-30 | Ubs Financial Services, Inc. | System and method for execution of trades made pursuant to stock option and purchase plans |
| RU2262950C2 (ru) * | 2001-03-23 | 2005-10-27 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | Способ получения вакцины для лечения туберкулеза и других внутриклеточных инфекционных заболеваний и вакцина, полученная по названному способу |
| GB0125535D0 (en) * | 2001-10-24 | 2001-12-12 | Microbiological Res Authority | Mycobacterial genes down-regulated during latency |
| PL2426141T3 (pl) * | 2005-04-29 | 2015-02-27 | Glaxosmithkline Biologicals Sa | Sposób profilaktyki lub leczenia zakażenia m. tuberculosis |
| US20070244199A1 (en) * | 2006-02-08 | 2007-10-18 | Fasgen Inc. | Anti-mycobacterial formulation |
| CN101516396B (zh) | 2006-09-26 | 2013-10-09 | 传染性疾病研究院 | 包含合成佐剂的疫苗组合物 |
| MX2009010800A (es) * | 2007-04-04 | 2010-01-29 | Infectious Disease Res Inst Id | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
| WO2010010178A1 (en) * | 2008-07-25 | 2010-01-28 | Glaxosmithkline Biologicals S.A | The tuberculosis rv2707c protein, compositions and uses thereof |
| EP2385371B1 (en) * | 2008-09-22 | 2014-10-22 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| GB201008512D0 (en) * | 2010-05-21 | 2010-07-07 | Health Prot Agency | Mycobacterial antigen composition |
| AP3390A (en) * | 2010-09-20 | 2015-08-31 | Crucell Holland Bv | Therapeutic vaccination against active tuberculosis |
-
2013
- 2013-08-02 BR BR112015002483A patent/BR112015002483A2/pt not_active Application Discontinuation
- 2013-08-02 MX MX2015001557A patent/MX2015001557A/es unknown
- 2013-08-02 US US14/419,477 patent/US20150182612A1/en not_active Abandoned
- 2013-08-02 PT PT138363247T patent/PT2879701T/pt unknown
- 2013-08-02 EP EP13836324.7A patent/EP2879701B1/en active Active
- 2013-08-02 CN CN201380051732.7A patent/CN104812404A/zh active Pending
- 2013-08-02 EP EP23206775.1A patent/EP4299138A2/en active Pending
- 2013-08-02 JP JP2015525632A patent/JP2015525784A/ja active Pending
- 2013-08-02 HR HRP20240164TT patent/HRP20240164T1/hr unknown
- 2013-08-02 WO PCT/US2013/053482 patent/WO2014042780A1/en active Application Filing
- 2013-08-02 RU RU2015107435A patent/RU2659149C2/ru active
- 2013-08-02 ES ES13836324T patent/ES2969734T3/es active Active
-
2015
- 2015-02-24 ZA ZA2015/01242A patent/ZA201501242B/en unknown
-
2017
- 2017-03-24 ZA ZA2017/02091A patent/ZA201702091B/en unknown
-
2018
- 2018-09-10 US US16/126,285 patent/US11369672B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2879701A1 (en) | 2015-06-10 |
| ZA201501242B (en) | 2017-08-30 |
| JP2015525784A (ja) | 2015-09-07 |
| RU2659149C2 (ru) | 2018-06-28 |
| PT2879701T (pt) | 2024-02-12 |
| EP2879701A4 (en) | 2016-01-20 |
| ZA201702091B (en) | 2018-12-19 |
| US20150182612A1 (en) | 2015-07-02 |
| ES2969734T3 (es) | 2024-05-22 |
| RU2015107435A (ru) | 2016-09-27 |
| CN104812404A (zh) | 2015-07-29 |
| EP2879701B1 (en) | 2023-11-15 |
| BR112015002483A2 (pt) | 2017-11-07 |
| US11369672B2 (en) | 2022-06-28 |
| WO2014042780A1 (en) | 2014-03-20 |
| MX2015001557A (es) | 2015-10-08 |
| US20200038498A1 (en) | 2020-02-06 |
| EP4299138A2 (en) | 2024-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | CD8 T cells and Mycobacterium tuberculosis infection | |
| Zhang | Persistent and dormant tubercle bacilli and latent tuberculosis | |
| HRP20240164T1 (hr) | Pripravci i postupci za liječenje aktivne tuberkulozne infekcije mikobakterijama | |
| Fresnay et al. | Salmonella Typhi-specific multifunctional CD8+ T cells play a dominant role in protection from typhoid fever in humans | |
| Demangel et al. | Protection against aerosol Mycobacterium tuberculosis infection using Mycobacterium bovis Bacillus Calmette Guérin‐infected dendritic cells | |
| Connor et al. | A key role for lung‐resident memory lymphocytes in protective immune responses after BCG vaccination | |
| Fresnay et al. | Importance of Salmonella Typhi-responsive CD8+ T cell immunity in a human typhoid fever challenge model | |
| Deng et al. | Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin‐12p70 and Early Secretory Antigen Target‐6 fusion protein | |
| Ma et al. | Tuberculosis antigen‐induced expression of IFN‐α in tuberculosis patients inhibits production of IL‐1β | |
| Kwon et al. | Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K | |
| JP2015525784A5 (hr) | ||
| Guirado et al. | Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis | |
| Sugawara et al. | Protective efficacy of recombinant BCG Tokyo (Ag85A) in rhesus monkeys (Macaca mulatta) infected intratracheally with H37Rv Mycobacterium tuberculosis | |
| CN103266119B (zh) | 一种结核杆菌三抗原融合基因疫苗及其制备方法和应用 | |
| Rosenberg et al. | Systemic infection following BCG therapy | |
| Qin et al. | Apa2H1, the first head domain of Apa2 trimeric autotransporter adhesin, activates mouse bone marrow-derived dendritic cells and immunization with Apa2H1 protects against Actinobacillus pleuropneumoniae infection | |
| JP2017524661A (ja) | 新規な温度敏感性マイコバクテリア菌株を含むマイコバクテリア感染症に対するワクチン組成物 | |
| US20140322264A1 (en) | Therapeutic vaccination against active tuberculosis | |
| Kujur et al. | Caerulomycin A suppresses the differentiation of naive T cells and alleviates the symptoms of experimental autoimmune encephalomyelitis | |
| Liang et al. | Preventive effects of Mycobacterium tuberculosis DNA vaccines on the mouse model with latent tuberculosis infection | |
| Schwartz et al. | BCG infection in mice is promoted by naïve mesenchymal stromal cells (MSC) and suppressed by poly (A: U)-conditioned MSC | |
| Dannenberg Jr et al. | Pathophysiology and immunology | |
| US20060153880A1 (en) | Pharmaceutical use of alpha antigen or alpha antigen gene | |
| Jee et al. | IL-10 down-regulates the expression of survival associated gene hspX of Mycobacterium tuberculosis in murine macrophage | |
| JP5994127B2 (ja) | 新規な組換えｂｃｇワクチン |